<DOC>
	<DOCNO>NCT00345410</DOCNO>
	<brief_summary>Primary objective : assess effect AVE1625 weight loss period 24 week abdominally obese patient atherogenic dyslipidemia . Secondary objective : - To assess dose effect relationship AVE1625 HDL-cholesterol triglyceride plasma level period 24 week - To assess efficacy AVE1625 secondary parameter waist circumference metabolic parameter period 24 week - To assess safety tolerabillity AVE1625 period 24 week .</brief_summary>
	<brief_title>Dose-Ranging Study Evaluating AVE1625 Abdominally Obese Patients With Atherogenic Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Abdominal obese patient · Waist circumference &gt; 102 cm men &gt; 88 cm woman Dyslipidemia consist : Triglycerides ≥ 1.50 g/L ( i.e 1.69 mmol/L ) ≤ 7.0 g/L ( i.e . 7.90 mmol/L ) AND/OR HDLcholesterol &lt; 50 mg/dL ( i.e . 1.29 mmol/L ) woman &lt; 40 mg/dL ( i.e . 1.04 mmol/L ) men Pregnancy lactation Women childbearing potential medically approve contraception Patients type 1 diabetes Patients type 2 diabetes must stable dose oral antidiabetic drug ( exclude glitazones , exenatide , sulfonylurea nateglinide ) receive insulin therapy Patients clinically significant endocrine disease Patients anticoagulant ( heparin , warfarin ) bleeding disorder Clinically relevant disease interfere subject 's safety making implementation study protocol interpretation study result difficult Patients mental retardation clinically significant psychiatric disorder History concurrent substance abuse ( nicotine caffeine especially marijuana hashish ) Chronic systemic corticotherapy Patients weight change &gt; 5kg within 3 month prior screen Patients receive antiobesity drug drug weight reduction 3 month prior screen . The investigator evaluate whether reason patient may participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>obesity dyslipidemia</keyword>
</DOC>